drugset
drugset / Trial / NCT04314713

A Study to Evaluate the Intramuscular Administration of Scopolamine

NCT04314713 ↗

Phase 1 Terminated 32 enrolled Battelle Memorial Institute
RandomizedParallel-groupTriple-blindPrevention

Summary

To characterize the safety and tolerability profile of ascending doses of scopolamine hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection. And characterize the pharmacokinetics (PK) of ascending doses of Scopolamine HBT administered by IM injection

Timeline

Start
2020-06-02
Primary completion
2021-04-06
Completion
2021-05-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Scopolamine Unknown 0.005 mg/kg Intramuscular
Comparator Scopolamine Unknown 0.007 mg/kg Intramuscular
Comparator Scopolamine Unknown 0.011 mg/kg Intramuscular
Comparator Scopolamine Unknown 0.014 mg/kg Intramuscular
Comparator Scopolamine Unknown 0.021 mg/kg Intramuscular

Indications

organophosphate poisoning